SCHEMBL14670519

SCHEMBL14670519

COC(=O)C(Nc1nc(Cl)ncc1Cl)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.46
EGFR P00533 1/20 0.46
TACR3 P29371 9/20 0.45
LMNA P02545 1/20 0.45
BDKRB1 P46663 1/20 0.43
KMT2A Q03164 3/20 0.42
TACR2 P21452 3/20 0.41
TSHR P16473 2/20 0.41
MEN1 O00255 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
NFKB1 P19838 1/20 0.41
MTOR P42345 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL657875 0.84 PIN1 (0.43) ELANEEGFRTACR3LMNABDKRB1
SCHEMBL14670520 0.84 ACLY (0.43) TACR3LMNAKMT2AMEN1NPSR1
SCHEMBL15840842 0.82 HPGD (0.44) TACR3TSHRKDM4EALDH1A1CYP3A4
SCHEMBL14670528 0.78 MTTP (0.38) KMT2AKDM4EALDH1A1NPSR1
SCHEMBL15840843 0.78 ALDH1A1 (0.40) LMNATSHRKDM4EALDH1A1CYP3A4
SCHEMBL14663730 0.78 CDK19 (0.62)
SCHEMBL15836877 0.77 MTTP (0.39) BDKRB1KMT2AKDM4EALDH1A1NPSR1
SCHEMBL18488387 0.76 GALR3 (0.47) LMNAKMT2AMEN1ALDH1A1HSD17B10
SCHEMBL18489016 0.76 GALR3 (0.47) LMNAKMT2AMEN1ALDH1A1HSD17B10
SCHEMBL20421869 0.76 GALR3 (0.47) LMNAKMT2AMEN1ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179664-A1 Heterocyclyl Pyrimidine Analogues As JAK Inhibitors CELLZOME LIMITED (GB) 2014-06-26 US disclosed
US-20140179664-A1 Heterocyclyl Pyrimidine Analogues As JAK Inhibitors CELLZOME LIMITED (GB) 2014-06-26 US disclosed
WO-2013014162-A1 HETEROCYCLYL PYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2013-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179664-A1 Heterocyclyl Pyrimidine Analogues As JAK Inhibitors JAK1, JAK3, JAK2 ELANE 3200/4885EGFR 1927/4885TACR3 2515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.